CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CARsgen Therapeutics
Company Type: Therapeutic development
Main focus: Advancing cancer treatment through engineered CAR-T cell therapy
Company stage: Clinical
Diseases: Haematological malignancies and solid tumours
Genome-editing tool:
Funding stage: Series C
Location: Xuhui District, Shanghai, China
Website: Home | CARsgen
Pipeline: Pipeline | CARsgen
Partners: Huadong Medicine, Moderna, and HK inno.N Corporation
CARsgen Therapeutics is a biopharmaceutical company specialising in developing CAR-T therapies for cancer treatment. The company focuses on creating immunotherapies targeting solid and blood cancers. CARsgen's pipeline includes therapeutic candidates such as gastric cancer, glioblastoma, and multiple myeloma. Their research aims to improve the efficacy and safety of CAR-T treatments in oncology through innovative engineering of CAR-T cells, including gene knockouts.
